Novagen and PerkinElmer Develop an Automated Solution for Protein Purification.
MADISON, WI and BOSTON--(BUSINESS WIRE)--Aug. 1, 2002
Novagen, Inc., a leading provider of advanced reagents for molecular biology and proteomics research, and PerkinElmer, Inc. (NYSE:PKI), a leading provider of drug discovery, life science research and genetic disease screening solutions, today announced an agreement to co-market a novel new solution for high throughput, automated recombinant protein purification.
"Extending our range of powerful liquid handling technologies to streamline the developing science of proteomics is a major goal for PerkinElmer Life Sciences," said Warren Bock, vice president and general manager for liquid handling products. "We are first to market in this area because our systems are uniquely suited to integrate a broad range of products in all facets of drug discovery research."
"Novagen remains committed to offering only the highest quality reagents and kits, such as our RoboPop(TM) Purification Kits, which serve the emerging proteomics market," said Dr. Robert Mierendorf, president of Novagen and chief technology officer of CN Biosciences. "Our greatest satisfaction derives from providing tools that enable new discoveries."
The collaboration between PerkinElmer and Novagen has resulted in a breakthrough platform for automating labor-intensive steps involved in protein purification. Conventional purification methods are time consuming and labor intensive, requiring centrifugation and mechanical steps for cell harvest and lysis prior to purification. Using PerkinElmer's MultiPROBE(R) II EX Robotic Liquid Handler and Novagen's RoboPop(TM) Protein Purification Kits, the platform performs 96-well format purification of His-Tag(R) and GST-Tag(TM) fusion proteins directly from E. coli cultures without mechanical lysis or centrifugation.
Novagen's RoboPop System is uniquely suited for automated protein purification because it eliminates the need for centrifugation and enables the entire process from cell growth through purification to be performed in a single deep well plate. The kits feature PopCulture(TM) Reagent, rLysozyme(TM) Solution, and Benzonase(R) Nuclease for efficient extraction of intact proteins from total cultures, plus His-Mag(TM) or GST-Mag(TM) Agarose Beads and corresponding buffers for high capacity magnetic affinity purification.
The MultiPROBE II EX system, when integrated with PerkinElmer's Gripper(TM) Integration Platform, allows for complete walk-away automation of the magnetic affinity purification protocol. The system's expanded deck configuration accommodates the RoboPop culture plate, reagents and Magnetight(TM) HT96(TM) Separation Stand. The RoboPop kits include everything needed to achieve the entire process, from cell culture of 96 recombinant clones to purified protein in an HTP 96-well format, including reagents and plasticware.
Factor Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including a downturn in our customers' markets, our failure to introduce new products in a timely manner, risks related to our international operations, our inability to integrate acquired businesses into our existing business, competition and other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our annual report on Form 10-K for the fiscal year ended December 30, 2001. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Novagen, Inc., a brand of CN Biosciences, an affiliate of Merck KGaA, Darmstadt, Germany, provides innovative molecular biology and proteomics products to the worldwide scientific research community. With more than 34,000 employees in 55 countries, the Merck Group generated sales of EUR 7.5 billion in 2001. Founded in 1668 in Darmstadt, Germany, the company aims to be a world leader in its core businesses of pharmaceuticals and chemicals. The Merck Group strongly believes the key to its long-term business success is innovative products created by entrepreneurial and talented employees. Merck groups its operating activities under Merck KGaA, in which the Merck family holds 74% and the remaining 26% is publicly traded. The former U.S. subsidiary, Merck & Co., has been a completely independent company since 1917.
PerkinElmer, Inc. is a global technology leader focused in three businesses - Life Sciences, Optoelectronics and Analytical Instruments. Combining operational excellence and technology expertise with an intimate understanding of our customers' needs, PerkinElmer creates innovative solutions - backed by unparalleled service and support - for customers in health sciences, communications and other markets whose applications demand precision and speed. The company operates in more than 125 countries and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
|Printer friendly Cite/link Email Feedback|
|Comment:||Novagen and PerkinElmer Develop an Automated Solution for Protein Purification.|
|Date:||Aug 1, 2002|
|Previous Article:||EquityOutlook.Com Announces Stock Evaluation Ratings: New Ratings on Nortel Networks, Verizon Communications, Johnson & Johnson, KLA-Tencor, and...|
|Next Article:||StockPickReport.com Announces Stock Evaluation Ratings: New Ratings on Cisco Systems, Williams Companies, Pfizer, Applied Materials, and Palm.|